SalaryGuide
AboutPricingFor Employers

Marketing jobs

2 marketing jobs

Eli Lilly and Company logo
3 weeks ago

Associate/Sr. Associate/Manager - Content Operations

Eli Lilly and Company

Indianapolis, IN (On-site)Full time$59K/yr – $138K/yr
Eli Lilly and Company logo
3 weeks ago

Associate/Sr. Associate/Manager Content Operations

Eli Lilly and Company

Indianapolis, IN (On-site)Full time$59K/yr – $138K/yr

Find marketing roles you could actually win

2 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media

Find marketing roles you could actually win

2 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media
2 jobs
Eli Lilly and Company logo

Associate/Sr. Associate/Manager - Content Operations

Eli Lilly and Company

Indianapolis, IN (On-site)

$59K/yr - $138K/yrIn-houseFull-timeSenior level2+ years exp.
3 weeks ago
Eli Lilly and Company logo

Associate/Sr. Associate/Manager Content Operations

Eli Lilly and Company

Indianapolis, IN (On-site)

$59K/yr - $138K/yrIn-houseFull-timeSenior level2+ years exp.
3 weeks ago
Eli Lilly and Company logo
Eli Lilly and Company

Associate/Sr. Associate/Manager - Content Operations

Indianapolis, IN (On-site)

$59K/yr – $138K/yrSenior Level2+ years expFull time

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own end-to-end content operations for brand backlog with an emphasis on on-time delivery, quality control, and compliant processes across the content supply chain.

  • Own brand content backlog timelines and ensure on-time delivery aligned to brand strategy.
  • Drive capacity, velocity, and throughput improvements via content ops tooling and cross-functional coordination.
  • Upskill partners on systems, workflows, and quality controls to reduce deviations and rework.

Job Description

Responsibilities

  • Define, oversee, and maintain an overall timeline for all projects within the brand’s backlog in partnership with internal and external agency, brand, review, and operations teammates.
  • Ensure the prompt and successful delivery of projects according to marketing needs and objectives
  • Proactively identify and resolve issues before they impact the business
  • Train and upskill cross functional partners on content supply chain systems and workflows
  • Partner in the deviation process, and log deviations using quality management system, and pass on to internal quality process department to conduct investigation into why, how and how to prevent in future
  • Use system tools to optimize team capacity, velocity, and throughput and coordinate with cross-functional peers to assess resource capacity and devise solutions to address resource constraints
  • Review timelines and capacity constraints for their given brands
  • Supervise errors, and work solution fixes, and technology to ensure accurate measurement of work to be done, capacity, resources required, forecasting, and content operations
  • They are responsible for checking work thoroughly between content supply chain systems and handoffs
  • They ensure data accuracy and track progress across content supply chain systems

Requirements

  • Bachelor’s degree
  • 2+ years of experience working on projects supporting a regulated industry (e.g., pharma)
  • 2+ years of experience with capacity and project management systems (e.g., Wrike/Workfront/Jira)
  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1

Preferred

  • Team-first approach
  • Growth perspective; proven willingness and ability to ingest feedback, reflect, and learn
  • Demonstrated strong verbal and written communication skills
  • Validated planning and organizational skills
  • Confirmed ability to handle multiple projects at a time
  • Record to influence, collaborate and work effectively on a team
  • Ability to understand, implement and guide technical knowledge across technologies, systems, and workflows
  • Ability to anticipate and resolve problems across systems and workflows
  • Ability to establish key relationships with cross-functional business areas

Benefits

  • including eligibility to participate in a company-sponsored 401(k); pension; vacation benefits; eligibility for medical, dental, vision and prescription drug benefits; flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts); life insurance and death benefits; certain time off and leave of absence benefits; and well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities).
Eli Lilly and Company logo

Eli Lilly and Company

4.1 Glassdoor

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.General Information and Guidelines:When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Founded in 1968
Indianapolis, Indiana, USA
53K employees (3,172 in marketing)
www.lilly.com
80% recommend to a friend
92% CEO approval

Traffic Signals

Monthly Visitors
4.3M
Monthly Google Ads Budget
$2.1M
Traffic Source Mix
Search
48.5%
Direct
37.7%
Referral
7.7%
Social
3.1%
Paid
2.9%

Headcount Trend

Current headcount: ~53.4K

Marketing Team

Marketing Team Size
2,777 (5% of company)
Median Career Experience
18 years
Median Tenure
12.1 years
Marketing Roles Posted (Last 30 Days)
7

People

HR / Recruitment

Maurice Taylor 🏃🏾‍♂️ 🏊🏾‍♂️ 🚴🏾
Maurice Taylor 🏃🏾‍♂️ 🏊🏾‍♂️ 🚴🏾
Executive Director of Talent Attraction, Recruitment Marketing and Workforce Equity Programs
At the company for 26 years 11 months

Marketing Leadership

Prentice Stovall
Prentice Stovall
Sr. Vice President, Immunology Strategy & Global Marketing - Chief Marketing Officer
At the company for 17 years 2 months
Juan Granados-Zuniga
Juan Granados-Zuniga
Vice President - Chief Marketing Officer Germany Hub
At the company for 22 years 2 months
Roberto Servi
Roberto Servi
Sr. Vice President Global Marketing and Chief Marketing Officer, Neuroscience Business Unit
At the company for 22 years 7 months
Susan Betito Vandewalle
Susan Betito Vandewalle
Business Unit Director Biomedicines and Chief Marketing Officer - Frennch Hub
At the company for 23 years 4 months

Funding

Total Funding
$6.5B
Last Raise
$6.5B
Post IPO Debt, 2 years ago

Funding History

  • Feb 2024
    Post IPO Debt • $6.5B

Recent News

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity
Oct 6, 2025 • Reuters
Eli Lilly and Company (LLY) Opens a New Lilly Gateway Labs Innovation Hub in San Diego
Sep 30, 2025 • Yahoo Finance
Indian stock market: 10 things that changed for market over weekend- Gift Nifty, Trump tariffs to US govt shutdown fears
Sep 29, 2025 • Livemint.com
Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating
Sep 29, 2025 • Morningstar.com
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
Sep 29, 2025 • Investing.com
Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States
Sep 29, 2025 • Morningstar.com
World shares trade mostly higher after Wall Street snaps its 3-day losing streak
Sep 29, 2025 • BNN Bloomberg
San Francisco VA offers new therapies for early-stage Alzheimer’s
Sep 28, 2025 • Alaska VA Healthcare System
Novo Nordisk: A Guru Buy Amid the Selloff -- Do LEAPS Make Sense?
Sep 28, 2025 • GuruFocus
Where Will Recursion Pharmaceuticals Be in 5 Years?
Sep 28, 2025 • The Motley Fool
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
Sep 28, 2025 • The Motley Fool
Lilly opens fifth ‘gateway’ lab on Torrey Pines Mesa
Sep 27, 2025 • San Diego Union-Tribune
Eli Lilly upgraded at CFRA as minimal impact seen from pharma tariffs
Sep 26, 2025 • Seeking Alpha
Eli Lilly halts trial testing experimental muscle-preserving drug with Zepbound
Sep 25, 2025 • Reuters
Here’s What Dragged Eli Lilly and Company (LLY) Down in Q2
Sep 25, 2025 • Yahoo Finance
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Sep 24, 2025 • Reuters
Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices
Sep 24, 2025 • The Independent
Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics
Sep 24, 2025 • BioSpace
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Sep 24, 2025 • Reuters
Eli Lilly to Invest $6.5 Billion in New US Manufacturing Facility
Sep 24, 2025 • MarketScreener
Eli Lilly boss brands UK ‘worst country in Europe’ for cheap drug prices
Sep 23, 2025 • Financial Times
Governor Abbott Announces New Eli Lilly Manufacturing Investment In Harris County
Sep 23, 2025 • Office of the Texas Governor (.gov)
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Sep 23, 2025 • Reuters
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
Sep 23, 2025 • CNBC
Celltrion buys Eli Lilly’s New Jersey plant for $330 million
Sep 23, 2025 • The Korea Economic Daily Global Edition
Eli Lilly announces weight-loss drug to be manufactured at $6.5 billion site in Houston
Sep 23, 2025 • Houston Public Media
News | Drugmaker Eli Lilly to invest $6.5 billion to build largest US manufacturing campus of its kind
Sep 23, 2025 • CoStar
SEED Therapeutics Completes $30 Million Series A-3 Financing
Sep 23, 2025 • SEED Therapeutics
Eli Lilly Plans to Build $6.5 Billion Manufacturing Site in Houston
Sep 23, 2025 • MarketScreener
To Compete in Obesity, Late Entrants Invest Early in Manufacturing
Sep 23, 2025 • BioSpace
Economist Impact's 5th edition Future of Health Asia returns to Singapore amid rising technological disruption, chronic disease burdens and international trade tensions
Sep 23, 2025 • PR Newswire UK
Confidence on Hold Until Powell Weighs In
Sep 23, 2025 • MarketScreener
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
Sep 23, 2025 • MarketScreener
Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas
Sep 23, 2025 • Morningstar.com
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • Morningstar.com
SEED Therapeutics Completes $30 Million Series A-3 Financing
Sep 23, 2025 • BioSpace
India's Fortis to expand obesity clinics amid weight-loss therapy boom, CEO says
Sep 23, 2025 • Reuters
U.S. Active Pharmaceutical Ingredients (API) Market 2035: Growth, Trends & Strategic Insights
Sep 23, 2025 • EIN Presswire
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Sep 23, 2025 • Reuters
Marquis Who's Who Honors Tyrone Dwayne Squires, CPBS, for Excellence in Health Care
Sep 23, 2025 • 24-7 Press Release Newswire
Eli Lilly to build new $6.5B facility in Houston, Texas
Sep 23, 2025 • thefly.com
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • BioSpace
Health Care Climbs on Regulatory Doubts - Health Care Roundup
Sep 23, 2025 • Morningstar.com
South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility
Sep 23, 2025 • Morningstar.com
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • PR Newswire
Roche Targets Top Spot In Weight Loss Drug Market
Sep 22, 2025 • Benzinga.com
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 22, 2025 • BioSpace
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
Sep 22, 2025 • BioSpace
StockWatch: Data, Big Name Investors Drive Prime Medicine Stock Surge
Sep 22, 2025 • Genetic Engineering News
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
Sep 22, 2025 • Investing.com
Alzheimer’s Drug Franchise Decides Eli Lilly And Co.’s (LLY) Performance
Sep 22, 2025 • Yahoo Finance
Roche, muscling into weight-loss drug race, advances obesity treatment to late-stage trial
Sep 22, 2025 • MarketScreener
DexCom is under fire from accusations
Sep 22, 2025 • MarketScreener
Modulo Bio Joins Lilly Gateway Labs to Accelerate Development of Neuroimmune Therapies for ALS, FTD and Alzheimer's
Sep 22, 2025 • EIN Presswire
Innovent's weight-loss drug highlights China challenge for Novo, Lilly
Sep 22, 2025 • MarketScreener
Why copycat Ozempic is everywhere
Sep 21, 2025 • Business Insider
Is Novo Nordisk Stock a Buy Now?
Sep 20, 2025 • The Motley Fool
2 Magnificent S&P 500 Dividend Stocks Down 7% and 19% to Buy and Hold Forever
Sep 20, 2025 • The Motley Fool
Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease
Sep 19, 2025 • MedCity News
GLP-1 drugs on WHO Essential Medicines List: what’s the impact?
Sep 19, 2025 • Labiotech UG
Why Shares in Novo Nordisk Soared This Week
Sep 19, 2025 • The Motley Fool
Ozempic bests dulaglutide in reducing heart attack, stroke and death risk
Sep 19, 2025 • Pharma Letter
Where Will Eli Lilly Be in 3 Years?
Sep 19, 2025 • The Motley Fool
Innovent Announces Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes
Sep 19, 2025 • BioSpace
Weekly Recap: 13 Health Press Releases You Need to See
Sep 19, 2025 • PR Newswire
Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered
Sep 19, 2025 • BioSpace
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
Sep 19, 2025 • prnasia.com
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
Sep 18, 2025 • Benzinga.com
STAT+: Pharmalittle: We’re reading about dueling data from Lilly and Novo, a Roche deal, and much more
Sep 18, 2025 • STAT
Susan G. Komen® To Host MORE THAN PINK Walk in Oklahoma City This October
Sep 18, 2025 • Morningstar.com
Deep Dive: Oral Obesity Drugs on the Cusp
Sep 18, 2025 • BioSpace
Jerome, you're going to be in big trouble!
Sep 18, 2025 • MarketScreener
Eli Lilly Says Mounjaro Meets Endpoints in Study of Children, Adolescents With Type 2 Diabetes
Sep 18, 2025 • MarketScreener
Jerome, you're in for a rough ride!
Sep 18, 2025 • MarketScreener
GeneDx Appoints Dr. Thomas Fuchs to its Board of Directors
Sep 18, 2025 • MarketScreener
Lilly keeps its end up in duel with Novo Nordisk - this time in diabetes
Sep 18, 2025 • Pharma Letter
Big Pharma’s pullback from the UK could have serious side-effects for Ireland
Sep 18, 2025 • Irish Times
Lilly Chooses Virginia Site for $5B API Manufacturing Facility, with ADCs in Mind
Sep 17, 2025 • Genetic Engineering News
Lilly Paints ‘Competitive Profile’ for Obesity Pill With Detailed Late-Stage Data
Sep 17, 2025 • BioSpace
Berenberg sees opportunity for pharma cos despite policy risks; upgrades Novo
Sep 17, 2025 • Reuters
Eli Lilly and Company Announces Detailed Results from the Phase 3 ATTAIN-1 Trial
Sep 17, 2025 • MarketScreener
Lilly touts obesity drug lead in Europe, Asia, Middle East, aims for global push
Sep 17, 2025 • Zawya.com
Eli Lilly to invest $5bn in new Virginia plant
Sep 17, 2025 • MarketScreener
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
Sep 17, 2025 • PR Newswire
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill
Sep 17, 2025 • MarketScreener
FDA Takes Long Overdue Baby Step Toward Regulating Compounder Drug Ads
Sep 17, 2025 • BioSpace
Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill
Sep 17, 2025 • MarketScreener
Drug manufacturer Eli Lilly to build plant in Goochland, create 650 permanent jobs
Sep 16, 2025 • Virginia Mercury
Eli Lilly (LLY)’s Pharmaceutical Leadership as a Driver of Consistent Dividends
Sep 16, 2025 • Yahoo Finance
Eli Lilly building $5 billion drug manufacturing facility in Goochland
Sep 16, 2025 • WWBT
Eli Lilly to build a new $5B plant in Virginia (LLY:NYSE)
Sep 16, 2025 • Seeking Alpha
Eli Lilly aims to bring more manufacturing home — plus, the good and bad among our industrials
Sep 16, 2025 • CNBC
Eli Lilly and Company to invest in $5 billion facility in Goochland, Youngkin announces
Sep 16, 2025 • WRIC ABC 8News
Eli Lilly and Company (LLY) Unveils AI Platform to Enhance Drug Discovery
Sep 15, 2025 • Yahoo Finance
Low investor expectation for Novo's study testing its weight loss drug in Alzheimer's disease, Leerink says
Sep 15, 2025 • Reuters
Option traders moderately bearish in Eli Lilly with shares down 0.87%
Sep 15, 2025 • thefly.com
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
Sep 15, 2025 • Benzinga.com
AstraZeneca falls 3% on reports of £200 mln Cambridge expansion pause
Sep 15, 2025 • Investing.com
GLP-1s claim the longevity stage at ARDD
Sep 15, 2025 • Longevity.Technology - Latest News, Opinions, Analysis and Research
Why Novo Nordisk Stock Popped Today
Sep 15, 2025 • The Motley Fool